간세포암 치료제 시장 보고서(2026년)

Hepatocellular carcinoma drugs are medications used to treat primary liver cancer that arises from hepatocytes, the principal cells of the liver. Hepatocellular carcinoma typically develops in the presence of chronic liver conditions such as long-term hepatitis B or C infection, alcoholic liver disease, non-alcoholic fatty liver disease (NAFLD), or liver cirrhosis.

The main types of hepatocellular carcinoma drugs include brachytherapy and chemotherapy. Brachytherapy is a form of radiation therapy used in cancer treatment that involves the accurate placement of radioactive sources directly within or close to the tumor site. The radioactive materials commonly used in brachytherapy for hepatocellular carcinoma include iodine-125 and iridium-192. The major drug classes used in hepatocellular carcinoma treatment include PD-1/PD-L1 inhibitors and tyrosine kinase inhibitors, which are utilized in hospitals, clinics, cancer rehabilitation centers, and ambulatory surgical centers.

Tariffs have created both challenges and opportunities for the hepatocellular carcinoma drugs market by affecting the import and export of key active pharmaceutical ingredients and advanced biologics. The resulting increase in production and distribution costs has particularly impacted chemotherapy and targeted therapy segments in regions like North America, Europe, and Asia-Pacific, which rely heavily on international supply chains. While delays and higher costs have posed challenges, tariffs have also encouraged local manufacturing investments and collaborations, potentially reducing long-term dependency on imports and fostering regional innovation.

The hepatocellular carcinoma drugs market research report is one of a series of new reports from The Business Research Company that provides hepatocellular carcinoma drugs market statistics, including hepatocellular carcinoma drugs industry global market size, regional shares, competitors with a hepatocellular carcinoma drugs market share, detailed hepatocellular carcinoma drugs market segments, market trends and opportunities, and any further data you may need to thrive in the hepatocellular carcinoma drugs industry. This hepatocellular carcinoma drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The hepatocellular carcinoma drugs market size has grown strongly in recent years. It will grow from $1.25 billion in 2025 to $1.35 billion in 2026 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to chronic hepatitis b and c prevalence, high incidence of liver cirrhosis, rising alcohol consumption, limited treatment options, late-stage diagnosis of hepatocellular carcinoma.

The hepatocellular carcinoma drugs market size is expected to see strong growth in the next few years. It will grow to $1.89 billion in 2030 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to advancements in targeted therapy, growth of immunotherapy drugs, expansion of early screening programs, increasing healthcare infrastructure in emerging markets, rising adoption of personalized medicine. Major trends in the forecast period include targeted therapy development, immunotherapy advancements, personalized medicine adoption, early diagnosis & screening programs, combination therapy research.

The increasing incidence of hepatocellular carcinoma is anticipated to drive the expansion of the hepatocellular carcinoma drug market in the coming years. Hepatocellular carcinoma (HCC) is a primary malignant cancer of the liver and represents the most common type of liver cancer. It originates in hepatocytes, the main functional cells of the liver. The majority of HCC cases are associated with chronic hepatitis B or C infections or long-term liver cirrhosis. As the number of hepatocellular carcinoma cases continues to rise, demand for effective drug therapies to manage and treat the disease is increasing. For example, in 2023, according to a report published by the American Cancer Society, Inc., a US-based nationwide voluntary health organization, the estimated number of new liver cancer cases diagnosed among females in the United States rose from 12,660 in 2022 to 13,230 in 2023. As a result, the growing occurrence of hepatocellular carcinoma is contributing to the growth of the hepatocellular carcinoma drug market.

Major companies operating in the hepatocellular carcinoma drug market are concentrating on the development of innovative therapies such as immune checkpoint inhibitor combinations to improve outcomes for patients with advanced disease. Immune checkpoint inhibitor combinations involve the use of two complementary immunotherapies that target different immune regulatory pathways, thereby enhancing the body's antitumor immune response. For instance, in April 2025, the U.S. Food and Drug Administration approved the nivolumab-ipilimumab combination regimen for first-line treatment of adults with unresectable or metastatic hepatocellular carcinoma. This dual immunotherapy demonstrated improved overall survival and response rates compared with existing treatment options, expanding the systemic therapy landscape for advanced liver cancer.

In August 2023, Novartis AG, a Switzerland-based pharmaceutical company, acquired Chinook Therapeutics Inc. for approximately $3.2 billion. Through this acquisition, Novartis aimed to strengthen its research and development capabilities by leveraging Chinook's expertise and pipeline, supporting the advancement of therapies for severe and rare chronic diseases and contributing to Novartis's broader commitment to innovation in specialized therapeutic areas.

Major companies operating in the hepatocellular carcinoma drugs market are AbbVie Inc., Amgen Inc., Bayer AG, Bristol-Myers Squibb Company, Eisai Co.Ltd., Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG, Sanofi S.A., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Otsuka Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Sumitomo Dainippon Pharma Co. Ltd., Hengrui Medicine Co. Ltd., CSPC Pharmaceutical Group Limited, Hutchison China MediTech Limited, Jiangsu Hengrui Medicine Co. Ltd.

North America was the largest region in the hepatocellular carcinoma drug market in 2025. The regions covered in the hepatocellular carcinoma drugs market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the hepatocellular carcinoma drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The hepatocellular carcinoma drug market consists of revenues earned by entities by providing surgery, radiofrequency ablation, and radiation therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The hepatocellular carcinoma drug market also includes sales of cabozantinib, ramucirumab and pembrolizumab drugs used for the treatment of hepatocellular carcinoma drugs. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Hepatocellular Carcinoma Drugs Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses hepatocellular carcinoma drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for hepatocellular carcinoma drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hepatocellular carcinoma drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Brachytherapy; Chemotherapy
• 2) By Drug Class: PD-1/PD-L1 Inhibitors; Tyrosine Kinase Inhibitors
• 3) By End User: Hospitals; Clinics; Cancer Rehabilitation Centers; Ambulatory Surgical Centers
• Subsegments:
• 1) By Brachytherapy: Radioactive Seed Implants; Balloon-Activated Brachytherapy; Selective Internal Radiation Therapy
• 2) By Chemotherapy: Systemic Chemotherapy; Targeted Therapy Agents; Combination Chemotherapy Regimens; Adjuvant Chemotherapy
• Companies Mentioned: AbbVie Inc.; Amgen Inc.; Bayer AG; Bristol-Myers Squibb Company; Eisai Co.Ltd.; Eli Lilly and Company; Johnson & Johnson; Merck & Co. Inc.; Novartis AG; Pfizer Inc.; Takeda Pharmaceutical Company Limited; Teva Pharmaceutical Industries Ltd.; F. Hoffmann-La Roche Ltd; Gilead Sciences Inc.; Exelixis Inc.; Ipsen Pharma Biotech SAS; AstraZeneca plc; BeiGene Ltd.; Ono Pharmaceutical Co. Ltd.; Roche Holdings AG; Sanofi S.A.; Astellas Pharma Inc.; Daiichi Sankyo Company Limited; Otsuka Pharmaceutical Co. Ltd.; Kyowa Kirin Co. Ltd.; Sumitomo Dainippon Pharma Co. Ltd.; Hengrui Medicine Co. Ltd.; CSPC Pharmaceutical Group Limited; Hutchison China MediTech Limited; Jiangsu Hengrui Medicine Co. Ltd.
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.

Table of Contents

1. Executive Summary

• 1.1. Key Market Insights (2020-2035)
• 1.2. Visual Dashboard: Market Size, Growth Rate, Hotspots
• 1.3. Major Factors Driving the Market
• 1.4. Top Three Trends Shaping the Market

2. Hepatocellular Carcinoma Drugs Market Characteristics

• 2.1. Market Definition & Scope
• 2.2. Market Segmentations
• 2.3. Overview of Key Products and Services
• 2.4. Global Hepatocellular Carcinoma Drugs Market Attractiveness Scoring And Analysis
  • 2.4.1. Overview of Market Attractiveness Framework
  • 2.4.2. Quantitative Scoring Methodology
  • 2.4.3. Factor-Wise Evaluation
• Growth Potential Analysis, Competitive Dynamics Assessment, Strategic Fit Assessment And Risk Profile Evaluation
• 2.4.4. Market Attractiveness Scoring and Interpretation
• 2.4.5. Strategic Implications and Recommendations

3. Hepatocellular Carcinoma Drugs Market Supply Chain Analysis

• 3.1. Overview of the Supply Chain and Ecosystem
• 3.2. List Of Key Raw Materials, Resources & Suppliers
• 3.3. List Of Major Distributors and Channel Partners
• 3.4. List Of Major End Users

4. Global Hepatocellular Carcinoma Drugs Market Trends And Strategies

• 4.1. Key Technologies & Future Trends
  • 4.1.1 Artificial Intelligence & Autonomous Intelligence
  • 4.1.2 Biotechnology, Genomics & Precision Medicine
  • 4.1.3 Digitalization, Cloud, Big Data & Cybersecurity
  • 4.1.4 Industry 4.0 & Intelligent Manufacturing
  • 4.1.5 Internet Of Things (Iot), Smart Infrastructure & Connected Ecosystems
• 4.2. Major Trends
  • 4.2.1 Targeted Therapy Development
  • 4.2.2 Immunotherapy Advancements
  • 4.2.3 Personalized Medicine Adoption
  • 4.2.4 Early Diagnosis & Screening Programs
  • 4.2.5 Combination Therapy Research

5. Hepatocellular Carcinoma Drugs Market Analysis Of End Use Industries

• 5.1 Hospitals
• 5.2 Clinics
• 5.3 Cancer Rehabilitation Centers
• 5.4 Ambulatory Surgical Centers
• 5.5 Specialty Cancer Centers

6. Hepatocellular Carcinoma Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market

7. Global Hepatocellular Carcinoma Drugs Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis

• 7.1. Global Hepatocellular Carcinoma Drugs PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 7.2. Global Hepatocellular Carcinoma Drugs Market Size, Comparisons And Growth Rate Analysis
• 7.3. Global Hepatocellular Carcinoma Drugs Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
• 7.4. Global Hepatocellular Carcinoma Drugs Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)

8. Global Hepatocellular Carcinoma Drugs Total Addressable Market (TAM) Analysis for the Market

• 8.1. Definition and Scope of Total Addressable Market (TAM)
• 8.2. Methodology and Assumptions
• 8.3. Global Total Addressable Market (TAM) Estimation
• 8.4. TAM vs. Current Market Size Analysis
• 8.5. Strategic Insights and Growth Opportunities from TAM Analysis

9. Hepatocellular Carcinoma Drugs Market Segmentation

• 9.1. Global Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Brachytherapy, Chemotherapy
• 9.2. Global Hepatocellular Carcinoma Drugs Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• PD-1/PD-L1 Inhibitors, Tyrosine Kinase Inhibitors
• 9.3. Global Hepatocellular Carcinoma Drugs Market, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Hospitals, Clinics, Cancer Rehabilitation Centers, Ambulatory Surgical Centers
• 9.4. Global Hepatocellular Carcinoma Drugs Market, Sub-Segmentation Of Brachytherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Radioactive Seed Implants, Balloon-Activated Brachytherapy, Selective Internal Radiation Therapy
• 9.5. Global Hepatocellular Carcinoma Drugs Market, Sub-Segmentation Of Chemotherapy, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• Systemic Chemotherapy, Targeted Therapy Agents, Combination Chemotherapy Regimens, Adjuvant Chemotherapy

10. Hepatocellular Carcinoma Drugs Market Regional And Country Analysis

• 10.1. Global Hepatocellular Carcinoma Drugs Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
• 10.2. Global Hepatocellular Carcinoma Drugs Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

11. Asia-Pacific Hepatocellular Carcinoma Drugs Market

• 11.1. Asia-Pacific Hepatocellular Carcinoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 11.2. Asia-Pacific Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

12. China Hepatocellular Carcinoma Drugs Market

• 12.1. China Hepatocellular Carcinoma Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 12.2. China Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

13. India Hepatocellular Carcinoma Drugs Market

• 13.1. India Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

14. Japan Hepatocellular Carcinoma Drugs Market

• 14.1. Japan Hepatocellular Carcinoma Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 14.2. Japan Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

15. Australia Hepatocellular Carcinoma Drugs Market

• 15.1. Australia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

16. Indonesia Hepatocellular Carcinoma Drugs Market

• 16.1. Indonesia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

17. South Korea Hepatocellular Carcinoma Drugs Market

• 17.1. South Korea Hepatocellular Carcinoma Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 17.2. South Korea Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

18. Taiwan Hepatocellular Carcinoma Drugs Market

• 18.1. Taiwan Hepatocellular Carcinoma Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 18.2. Taiwan Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

19. South East Asia Hepatocellular Carcinoma Drugs Market

• 19.1. South East Asia Hepatocellular Carcinoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 19.2. South East Asia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

20. Western Europe Hepatocellular Carcinoma Drugs Market

• 20.1. Western Europe Hepatocellular Carcinoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 20.2. Western Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

21. UK Hepatocellular Carcinoma Drugs Market

• 21.1. UK Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

22. Germany Hepatocellular Carcinoma Drugs Market

• 22.1. Germany Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

23. France Hepatocellular Carcinoma Drugs Market

• 23.1. France Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

24. Italy Hepatocellular Carcinoma Drugs Market

• 24.1. Italy Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

25. Spain Hepatocellular Carcinoma Drugs Market

• 25.1. Spain Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

26. Eastern Europe Hepatocellular Carcinoma Drugs Market

• 26.1. Eastern Europe Hepatocellular Carcinoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 26.2. Eastern Europe Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

27. Russia Hepatocellular Carcinoma Drugs Market

• 27.1. Russia Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

28. North America Hepatocellular Carcinoma Drugs Market

• 28.1. North America Hepatocellular Carcinoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 28.2. North America Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

29. USA Hepatocellular Carcinoma Drugs Market

• 29.1. USA Hepatocellular Carcinoma Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 29.2. USA Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

30. Canada Hepatocellular Carcinoma Drugs Market

• 30.1. Canada Hepatocellular Carcinoma Drugs Market Overview
• Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 30.2. Canada Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

31. South America Hepatocellular Carcinoma Drugs Market

• 31.1. South America Hepatocellular Carcinoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 31.2. South America Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

32. Brazil Hepatocellular Carcinoma Drugs Market

• 32.1. Brazil Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

33. Middle East Hepatocellular Carcinoma Drugs Market

• 33.1. Middle East Hepatocellular Carcinoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 33.2. Middle East Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

34. Africa Hepatocellular Carcinoma Drugs Market

• 34.1. Africa Hepatocellular Carcinoma Drugs Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 34.2. Africa Hepatocellular Carcinoma Drugs Market, Segmentation By Type, Segmentation By Drug Class, Segmentation By End User, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion

35. Hepatocellular Carcinoma Drugs Market Regulatory and Investment Landscape

36. Hepatocellular Carcinoma Drugs Market Competitive Landscape And Company Profiles

• 36.1. Hepatocellular Carcinoma Drugs Market Competitive Landscape And Market Share 2024
  • 36.1.1. Top 10 Companies (Ranked by revenue/share)
• 36.2. Hepatocellular Carcinoma Drugs Market - Company Scoring Matrix
  • 36.2.1. Market Revenues
  • 36.2.2. Product Innovation Score
  • 36.2.3. Brand Recognition
• 36.3. Hepatocellular Carcinoma Drugs Market Company Profiles
  • 36.3.1. AbbVie Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.2. Amgen Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.3. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 36.3.5. Eisai Co.Ltd. Overview, Products and Services, Strategy and Financial Analysis

37. Hepatocellular Carcinoma Drugs Market Other Major And Innovative Companies

• Eli Lilly and Company, Johnson & Johnson, Merck & Co. Inc., Novartis AG, Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., F. Hoffmann-La Roche Ltd, Gilead Sciences Inc., Exelixis Inc., Ipsen Pharma Biotech SAS, AstraZeneca plc, BeiGene Ltd., Ono Pharmaceutical Co. Ltd., Roche Holdings AG

38. Global Hepatocellular Carcinoma Drugs Market Competitive Benchmarking And Dashboard

39. Key Mergers And Acquisitions In The Hepatocellular Carcinoma Drugs Market

40. Hepatocellular Carcinoma Drugs Market High Potential Countries, Segments and Strategies

• 40.1 Hepatocellular Carcinoma Drugs Market In 2030 - Countries Offering Most New Opportunities
• 40.2 Hepatocellular Carcinoma Drugs Market In 2030 - Segments Offering Most New Opportunities
• 40.3 Hepatocellular Carcinoma Drugs Market In 2030 - Growth Strategies
  • 40.3.1 Market Trend Based Strategies
  • 40.3.2 Competitor Strategies

41. Appendix

• 41.1. Abbreviations
• 41.2. Currencies
• 41.3. Historic And Forecast Inflation Rates
• 41.4. Research Inquiries
• 41.5. The Business Research Company
• 41.6. Copyright And Disclaimer